title: Celecoxib sensitizes Staphylococcus aureus to antibiotics in macrophages by modulating SIRT1.
abstract: We have previously shown that celecoxib in combination with an antibiotic, increase the bacterial sensitivity to antibiotics. However, the underlying molecular mechanism remained elusive. Efficacy of the combinatorial treatment of celecoxib and ampicillin in vitro was evaluated on macrophage-phagocytosed S. aureus. To elucidate the mechanism, signaling pathway of infection and inflammation involving TLR2, JNK, SIRT1 and NF-κB was studied by FACS, Western blot, ELISA and activity assays. Combinatorial treatment of ampicillin and celecoxib reduced the bacterial load in the macrophages. Further studies clearly suggested the activation of the master regulator of oxidative stress and inflammation SIRT1, by celecoxib when used alone and/or in combination with ampicillin. Also, the results indicated that celecoxib inhibited JNK phosphorylation thereby stabilizing and activating SIRT1 protein that inhibited the COX-2 gene transcription with a significant decrease in the levels of protein inflammatory cytokines like IL-6, MIP-1α and IL-1β via inhibition of NF-κB. SIRT1 activation by celecoxib also resulted in increase of catalase and peroxidase activity with a decrease in Nitric oxide levels. In conclusion, we demonstrate a novel role of celecoxib in controlling inflammation as an enhancer of antibiotic activity against bacteria by modulating SIRT1.
authors.affiliation: Department of Animal Sciences, School of Life Sciences, University of Hyderabad, Hyderabad, India.
authors.forename: Madhavi
authors.initials: M
authors.lastname: Annamanedi
authors.affiliation: Department of Animal Sciences, School of Life Sciences, University of Hyderabad, Hyderabad, India.
authors.forename: Arunasree M
authors.initials: AM
authors.lastname: Kalle
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000068579:Celecoxib; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000235:genetics; D008264:Macrophages / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D051379:Mice; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress / Q000235:genetics; D011720:Pyrazoles / Q000008:administration & dosage*; D015398:Signal Transduction / Q000187:drug effects; D056564:Sirtuin 1 / Q000096:biosynthesis / Q000378:metabolism*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000235:genetics / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000472:pathogenicity; D013449:Sulfonamides / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D011720:Pyrazoles; D013449:Sulfonamides; D009569:Nitric Oxide; C470545:Sirt1 protein, mouse; D056564:Sirtuin 1; D000068579:Celecoxib